Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
Bacterial vaginosis affects nearly 20 million women in the U.S. every year SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling
SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.
SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018 , to provide a corporate update and
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place
SAN DIEGO , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October
SAN DIEGO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership
SAN DIEGO , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will present at the 2018 BIO Investor Forum on Wednesday, October 17, 2018
